Cited 5 times in
Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김법우 | - |
dc.contributor.author | 김석모 | - |
dc.contributor.author | 김수영 | - |
dc.contributor.author | 김준원 | - |
dc.contributor.author | 박정수 | - |
dc.contributor.author | 이용상 | - |
dc.contributor.author | 이익재 | - |
dc.contributor.author | 장항석 | - |
dc.contributor.author | 장호진 | - |
dc.contributor.author | 전태주 | - |
dc.date.accessioned | 2020-12-01T17:20:46Z | - |
dc.date.available | 2020-12-01T17:20:46Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180226 | - |
dc.description.abstract | Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging. Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64-839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9-10%. The other 16 patients (88.9%) had tumor volume reductions of 2-69%. Six patients (33.3%) had tumor volume reductions ≥50%. Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Research | - |
dc.relation.isPartOf | FRONTIERS IN ENDOCRINOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Soo Young Kim | - |
dc.contributor.googleauthor | Seok-Mo Kim | - |
dc.contributor.googleauthor | Jun Won Kim | - |
dc.contributor.googleauthor | Ik Jae Lee | - |
dc.contributor.googleauthor | Tae Joo Jeon | - |
dc.contributor.googleauthor | Hojin Chang | - |
dc.contributor.googleauthor | Bup-Woo Kim | - |
dc.contributor.googleauthor | Yong Sang Lee | - |
dc.contributor.googleauthor | Hang-Seok Chang | - |
dc.contributor.googleauthor | Cheong Soo Park | - |
dc.identifier.doi | 10.3389/fendo.2020.00599 | - |
dc.contributor.localId | A00491 | - |
dc.contributor.localId | A00542 | - |
dc.contributor.localId | A04725 | - |
dc.contributor.localId | A00958 | - |
dc.contributor.localId | A01646 | - |
dc.contributor.localId | A02978 | - |
dc.contributor.localId | A03055 | - |
dc.contributor.localId | A03488 | - |
dc.contributor.localId | A03496 | - |
dc.contributor.localId | A03557 | - |
dc.relation.journalcode | J03412 | - |
dc.identifier.eissn | 1664-2392 | - |
dc.identifier.pmid | 32982983 | - |
dc.subject.keyword | anaplastic thyroid cancer | - |
dc.subject.keyword | lenvatinib | - |
dc.subject.keyword | retrospective study | - |
dc.subject.keyword | thyroid carcinoma | - |
dc.subject.keyword | tyrosine kinase inhibitor | - |
dc.contributor.alternativeName | Kim, Bup Woo | - |
dc.contributor.affiliatedAuthor | 김법우 | - |
dc.contributor.affiliatedAuthor | 김석모 | - |
dc.contributor.affiliatedAuthor | 김수영 | - |
dc.contributor.affiliatedAuthor | 김준원 | - |
dc.contributor.affiliatedAuthor | 박정수 | - |
dc.contributor.affiliatedAuthor | 이용상 | - |
dc.contributor.affiliatedAuthor | 이익재 | - |
dc.contributor.affiliatedAuthor | 장항석 | - |
dc.contributor.affiliatedAuthor | 장호진 | - |
dc.contributor.affiliatedAuthor | 전태주 | - |
dc.citation.volume | 11 | - |
dc.citation.startPage | 599 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ENDOCRINOLOGY, Vol.11 : 599, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.